GXB works as one group organised around three complementary research lines. Each line is led by one or more principal investigators, and the lines share methods, expertise and projects.
Genomics of disease and pathogens
Cancer evolution through single-cell genomics and liquid biopsy, molecular evolution of viruses such as HIV-1, SARS-CoV-2 and CCHFV and their resistance to treatments, and evolutionary genomics for the conservation of biological resources.
David Posada · Miguel Arenas · Iria Fernández-Silva
Molecular biology applied to biomedicine
Genetic basis of rare ciliopathies and pulmonary arterial hypertension, and mechanisms of ageing in cancer and osteoarthritis, in search of new biomarkers and therapeutic targets.
Diana Valverde · María Mayán
Nanomaterials for biomedicine
Green-chemistry nanomaterials with antitumour and antimicrobial activity, drug-delivery systems and new therapies against cancer.
Carmen Rodríguez-Argüelles · María Mayán
Working together
Collaboration across lines is a central part of how we work: evolutionary and computational approaches developed in the genomics line support the analysis of clinical and experimental data in the biomedicine and nanomaterials lines, and joint projects and papers bring the investigators together.
- Genomic epidemiology of SARS-CoV-2. Several GXB investigators contributed to reconstructing the arrival and spread of the virus in Spain and Europe (Nature Genetics 2021, Nature 2021, Virus Evolution 2022).
- Evolutionary models for biomedicine. Methods from molecular evolution are used to interpret rare human variants and viral drug resistance, for example ABCC8 variants in pulmonary arterial hypertension (Scientific Reports 2020).
- A shared programme. Common funding as a Competitive Reference Group of the Xunta de Galicia and a joint seminar series that brings the whole team together.